tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GANX Stock Latest News

Gain Therapeutics price target lowered to $6 from $7 at Roth Capital
The FlyGain Therapeutics price target lowered to $6 from $7 at Roth Capital
7h ago
GANX
Gain Therapeutics reports Q2 EPS (19c), consensus (17c)
PremiumThe Fly
Gain Therapeutics reports Q2 EPS (19c), consensus (17c)
19h ago
GANX
Gain Therapeutics Announces $7 Million Public Offering
PremiumCompany Announcements
Gain Therapeutics Announces $7 Million Public Offering
27d ago
8K
GANX
Gain Therapeutics 7M share Spot Secondary priced at $1.55
PremiumThe Fly
Gain Therapeutics 7M share Spot Secondary priced at $1.55
28d ago
GANX
Gain Therapeutics prices 4.50M offering at $1.55 per share
PremiumThe Fly
Gain Therapeutics prices 4.50M offering at $1.55 per share
28d ago
GANX
Gain Therapeutics announces common stock, warrants offering
PremiumThe FlyGain Therapeutics announces common stock, warrants offering
28d ago
GANX
Buy Rating for Gain Therapeutics Driven by Accelerated Clinical Progress and Valuation Model
Premium
Ratings
Buy Rating for Gain Therapeutics Driven by Accelerated Clinical Progress and Valuation Model
1M ago
GANX
Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating
Premium
Ratings
Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating
1M ago
GANX
Positive Outlook for Gain Therapeutics Amid Promising Biomarker Developments and Clinical Trial Progress
PremiumRatings
Positive Outlook for Gain Therapeutics Amid Promising Biomarker Developments and Clinical Trial Progress
1M ago
GANX
Gain Therapeutics Advances Phase 1b Parkinson’s Study
PremiumCompany Announcements
Gain Therapeutics Advances Phase 1b Parkinson’s Study
1M ago
8K
GANX
Gain Therapeutics Doubles Authorized Common Stock Shares
PremiumCompany Announcements
Gain Therapeutics Doubles Authorized Common Stock Shares
2M ago
8K
GANX
Gain Therapeutics files $100M mixed securities shelf
PremiumThe Fly
Gain Therapeutics files $100M mixed securities shelf
3M ago
GANX
Buy Rating for Gain Therapeutics: Promising Phase 1b Trial and Strong Financial Position Support Positive Outlook
PremiumRatingsBuy Rating for Gain Therapeutics: Promising Phase 1b Trial and Strong Financial Position Support Positive Outlook
3M ago
GANX
Buy Rating for Gain Therapeutics Driven by Promising Parkinson’s Program and Strong Financial Position
Premium
Ratings
Buy Rating for Gain Therapeutics Driven by Promising Parkinson’s Program and Strong Financial Position
3M ago
GANX
Gain Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Gain Therapeutics Reports Q1 2025 Financial Results
3M ago
GANX
Gain Therapeutics reports Q1 EPS (16c), consensus (18c)
PremiumThe Fly
Gain Therapeutics reports Q1 EPS (16c), consensus (18c)
3M ago
GANX
Gain Therapeutics reports preclinical data n GT-02287
PremiumThe Fly
Gain Therapeutics reports preclinical data n GT-02287
3M ago
GANX
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
PremiumRatings
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
3M ago
GANX
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating
PremiumRatings
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating
4M ago
GANX
Gain Therapeutics Unveils New Parkinson’s Treatment Data
PremiumCompany AnnouncementsGain Therapeutics Unveils New Parkinson’s Treatment Data
4M ago
8K
GANX
Gain Therapeutics presents additional data on study of GT-02287
Premium
The Fly
Gain Therapeutics presents additional data on study of GT-02287
4M ago
GANX
Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
Premium
Ratings
Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
5M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >